Related Experiment Videos

[Controlled release metoprolol succinate in MERIT-HF. Analysis of patients subgroups]

B A Sidorenko1, M A Bugrimova, I K Iosava

  • 1Presidential Medical Center of Russia, Moscow, Russia.

Kardiologiia
|April 24, 2008
PubMed

Insights

Metoprolol CR/XL significantly reduced mortality in patients with chronic heart failure (CHF). This beta-blocker demonstrated consistent effectiveness across diverse patient subgroups, including different age groups and genders.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Trials

Context:

  • Chronic heart failure (CHF) poses a significant mortality risk.
  • Beta-blockers are a cornerstone therapy for heart failure.
  • The MERIT-HF study investigated metoprolol CR/XL in CHF patients.

Purpose:

  • To evaluate the efficacy of metoprolol controlled-release/extended-release (CR/XL) in reducing mortality in patients with chronic heart failure (CHF).
  • To analyze the effectiveness of metoprolol CR/XL across various patient subgroups.

Summary:

  • The large randomized controlled MERIT-HF study demonstrated that metoprolol CR/XL, a beta1-selective blocker, lowered overall mortality in patients with CHF.
  • Subgroup analyses confirmed metoprolol CR/XL's consistent efficacy in middle-aged and elderly patients, as well as in both men and women.

Impact:

  • Metoprolol CR/XL provides a mortality benefit for a broad range of chronic heart failure patients.
  • The findings support the use of metoprolol CR/XL as a standard treatment option for chronic heart failure.
  • Evidence supports personalized treatment approaches within CHF management based on drug efficacy across demographics.

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...